A Phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms and chronic myelomonocytic leukemia

PURPOSE: The poly(ADP-ribose) polymerase (PARP) inhibitor veliparib delays DNA repair and potentiates cytotoxicity of multiple classes of chemotherapy drugs, including topoisomerase I inhibitors and platinating agents. This study evaluated veliparib incorporation into leukemia induction therapy usin...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Pratz, Keith W., Rudek, Michelle A., Gojo, Ivana, Litzow, Mark R., McDevitt, Michael A., Ji, Jiuping, Karnitz, Larry M., Herman, James G., Kinders, Robert J., Smith, B. Douglas, Gore, Steven D., Carraway, Hetty E., Showel, Margaret M., Gladstone, Douglas E., Levis, Mark J., Tsai, Hua-Ling, Rosner, Gary, Chen, Alice, Kaufmann, Scott H., Karp, Judith E.
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5315611/
https://ncbi.nlm.nih.gov/pubmed/27551000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1274
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares